Related Experiment Video
Updated: Apr 5, 2026

Investigating Aortic Valve Calcification via Isolation and Culture of T Lymphocytes using Feeder Cells from Irradiated Buffy Coat
Published on: February 4, 2021
Lipid Interventions in Aortic Valvular Disease
Kwang Jin Choi1, Christiana Tsomidou, Stamatios Lerakis
1Department of Medicine (KJC), University of Chicago Medical Center, Chicago, Illinois; Department of Medicine (CT), General Hospital of Piraeus "Hippocrates," Piraeus, Greece; Department of Medicine (SL), Emory University School of Medicine, Atlanta, Georgia; St. Francis Hospital, The Heart Center (RM, TJV), Division of Cardiology, Center for Advanced Cardiac Therapeutics, Roslyn, New York; and Zena and Michael A. Wiener Cardiovascular Institute (CEK), Icahn School of Medicine at Mount Sinai, New York, New York.
Insights
Aortic stenosis (AS) involves lipid deposition and inflammation. Lipid interventions may slow AS progression, particularly in early stages, but further research is needed to confirm effectiveness.
Area of Science:
- Cardiovascular Medicine
- Valvular Heart Disease
- Atherosclerosis Research
Background:
- Aortic stenosis (AS) is a prevalent valvular disease in the elderly.
- AS pathogenesis shares similarities with atherosclerosis, involving lipid deposition, inflammation, fibrosis, and calcification.
- Current evidence on lipid interventions, like statins, for slowing AS progression is inconsistent.
Purpose of the Study:
- To explore the potential of lipid interventions in preventing or slowing aortic stenosis progression.
- To investigate the hypothesis that lipid interventions may be more effective in earlier stages of AS, characterized by inflammation.
- To evaluate the utility of positron emission tomography (PET) in differentiating inflammatory and calcific components of AS.
Main Methods:
- Review of current evidence on lipid interventions and their effect on AS progression.
- Discussion of the role of inflammation versus calcification in AS pathogenesis.
- Consideration of advanced imaging techniques like 18F-fluorodeoxyglucose and 18F-sodium fluoride PET scans.
- Exploration of novel therapeutic targets such as recombinant apolipoprotein A-1 Milano and agents targeting lipoprotein (a) and lipoprotein-associated phospholipase A2.
Main Results:
- Large clinical trials have not consistently shown statins to decrease AS progression.
- A potential benefit of statins in early-stage AS, where inflammation predominates, is suggested.
- Advanced AS stages are characterized by calcification, potentially limiting the efficacy of lipid-lowering therapies.
- Novel therapeutic strategies targeting lipoprotein (a) and related enzymes are under investigation.
Conclusions:
- Lipid interventions may hold promise for managing aortic stenosis, especially in its early, inflammatory phase.
- Positron emission tomography imaging could help stratify patients and guide therapeutic interventions.
- Further research into novel pharmacological agents is crucial for developing effective treatments for aortic stenosis.
Abstract:
Aortic valve stenosis is the most common valvular disease in the elderly population. Presently, there is increasing evidence that aortic stenosis (AS) is an active process of lipid deposition, inflammation, fibrosis and calcium deposition. The pathogenesis of AS shares many similarities to that of atherosclerosis; therefore, it was hypothesized that certain lipid interventions could prevent or slow the progression of aortic valve stenosis. Despite the early enthusiasm that statins may slow the progression of AS, recent large clinical trials did not consistently demonstrate a decrease in the progression of AS. However, some researchers believe that statins may have a benefit early on in the disease process, where inflammation (and not calcification) is the predominant process, in contrast to severe or advanced AS, where calcification (and not inflammation) predominates. Positron emission tomography using 18F-fluorodeoxyglucose and 18F-sodium fluoride can demonstrate the relative contributions of valvular calcification and inflammation in AS, and thus this method might potentially be useful in providing the answer as to whether lipid interventions at the earlier stages of AS would be more effective in slowing the progression of the disease. Currently, there is a strong interest in recombinant apolipoprotein A-1 Milano and in the development of new pharmacological agents, targeting reduction of lipoprotein (a) levels and possibly reduction of the expression of lipoprotein-associated phospholipase A2, as potential means to slow the progression of aortic valvular stenosis.
Related Concept Videos
Atherosclerosis III: Management
Aortic Regurgitation III: Medical Management
Atherosclerosis IV: Nursing Management
Peripheral Artery Disease III: Interprofessional Care
Coronary Artery Disease IV: Preventive Measures
Mitral Stenosis III: Medical Management
